



RONALD M. BUKOWSKI, MD, EDITOR

## From the Editor

**T**he diagnosis and treatment of neoplastic diseases continues to evolve. Progress in the field of biotechnology, including development of recombinant cytokines and monoclonal antibodies, as well as significant advances in our understanding of the biology of neoplasms has contributed to advancement in the therapy and diagnosis of these disorders. In view of these rapid changes, guidelines addressing current therapeutic management of various malignancies are necessary.

This *Cleveland Clinic Journal of Medicine* supplement is the second in a series of management guidelines for neoplastic diseases. Dr. Novick and I have critically reviewed renal cell carcinoma literature to define practice guidelines for the diagnosis and treatment of patients with this tumor.

The first supplement was created in 1995 with a focus on the non-Hodgkin's lymphomas. Future supplements will focus on such topics as melanoma.

The goal is to establish treatment pathways that will permit cancer care providers to improve patient outcomes while containing healthcare costs. These therapeutic management guidelines are being developed as a freestanding Continuing Medical Education publication. The objective of these supplements, and of other educational commitments intended for the near future, is to share up-to-date information crucial to our understanding of the diagnosis and therapy of the targeted cancers.

We hope you find this supplement to be of value. Please let us know your comments and suggestions; we would appreciate hearing from you.

RONALD M. BUKOWSKI, MD  
Cleveland Clinic Cancer Center